Corporate Antibodies. Why organisations kill the ventures they commission.

Everyone blames the idea

When a corporate venture dies, the post-mortem almost always points to the same culprit: wrong market, wrong timing, wrong product. The idea wasn't good enough. The team picked badly. And that story is comfortable because it means the organisation itself worked fine. The venture just didn't make it.

We've been embedded inside enough of these to know that's rarely true.

Most corporate ventures that fail have perfectly viable ideas. What kills them is the organisation's immune system. Procurement, IT security, legal, brand, finance: each one doing exactly what it was designed to do for the core business. And each one, inadvertently, rejecting the venture like a foreign body.

The immune system is rational. That's what makes it so dangerous. Every individual process exists for a good reason. Together, they add up to death by a thousand reasonable requests.

How the antibodies actually work

Here's a version of what we see in almost every engagement. A new venture needs a vendor onboarded. Procurement says six weeks, which is fast by their standards. But the pilot window closes in four. A data feed requires an IT security review. Three months, minimum. By the time it clears, the customer who agreed to the pilot has moved on to something else.

Legal wants product claims scrubbed. Marketing wants brand alignment. Finance wants a fully modelled business case before approving what amounts to petty cash. Each request is individually reasonable. And each one costs the venture something it can't get back: time.

"The conversations you avoid before launch are the crises you manage six months in."

Capgemini's research on corporate innovation labs quantifies what this feels like from the inside. Ninety percent of labs fail to deliver meaningful impact. CB Insights found that 60% of corporate accelerators shut down within two years. The pattern is consistent: internal processes designed for the core business become a gauntlet that early-stage ventures can't survive.

And it gets personal. Every person on a corporate venture team was doing something else before. Their old team still needs them. Their old manager still calls. Their performance review still references their original function. We see this constantly: the venture gets officially 100 percent of someone's time. It gets maybe 40 percent of their attention. Unless people are formally released, with their performance review moved to the venture, the pull back to core is constant. Eventually irresistible.

Four antibodies that kill the most ventures

The pattern repeats across industries and geographies. We've catalogued the antibodies that do the most damage, and they're remarkably consistent.

The sponsor problem is worse than you think

Every other antibody we've described is structural. You can map it, name it, negotiate around it. The sponsor problem is different because it's personal and political, and nobody puts it in the risk register.

CB Insights' research on corporate accelerators shows that 60% shut down within two years — and that the ones which survive share one trait: active, structural executive sponsorship. Deloitte Doblin's work on innovation capability reinforces this: organisations with formal governance around new ventures are nearly three times more likely to have incentive structures tied to venture outcomes. The data confirms what we see on the ground: sponsorship matters enormously, and most organisations treat it casually.

Here's what casual sponsorship looks like in practice. A senior leader backs a venture with genuine conviction. The venture gets budget, headcount, a mandate. Eighteen months in, that leader gets promoted to a different division. Or they inherit a new priority that crowds out the old one. Or they leave the company.

"People move. Structures persist. Build the governance to outlast any individual champion."

The venture's air cover evaporates overnight. The antibody response, which the sponsor had been quietly holding at bay, accelerates. Resources get redirected. The reporting line shifts to someone who didn't commission the work and doesn't feel ownership of it. We've watched this happen to perfectly viable ventures. The market hadn't changed. The org chart had.

The fix isn't to find a better sponsor. It's to build institutional ownership: a formal governance body with documented accountability that outlasts any individual. A steering board, with terms of reference, that treats the venture as a structural commitment rather than a personal favour.

Engineering around the immune system

The antibody response is real and it's rational, and that combination is what makes it so effective at killing ventures. You can't fight the immune system by pretending it isn't there. And you can't fight it by asking politely for exceptions.

What you can do is treat it as a design constraint from day one.

The organisations we've seen build successfully inside large structures share a common trait: they negotiate the operating model before the venture launches. They map the five most likely friction points and secure named authority to unblock each one. Key people get formally separated from their old functions. Governance gets built to outlast any single sponsor. And they do all of this before the venture ships anything, because once it's moving, the immune system moves faster.

We've been embedded inside these problems across 47 ventures in 12 countries. The pattern is remarkably consistent. The organisations that win aren't the ones with better ideas. They're the ones that understood, before launch, that the hardest part of building inside a large company isn't the market. It's the building.